http://www.fpnotebook.com/
Protease Inhibitor
- Mechanism
- Prevent HIV from being assembled
- Prevent release from infected CD4 cells
- Preparations
- Amprenavir (Agenerase)
- Atazanavir (Reyataz)
- Fosamprenavir (Lexiva)
- Converted to Agenerase in vivo
- Less gastrointestinal side effects than Agenerase
- CYP3A4 inhibitor
- Indinavir (Crixivan)
- Lopinavir with Ritonavir (Kaletra)
- Nelfinavir (Viracept)
- Ritonavir (Norvir)
- Saquinavir (Fortovase)
- Saquinavir mesylate (Invirase)
- Tipranavir (Aptivus)
- Indicated for resistance to other protease inhibitors
- Avoid if sulfa allergy
- Precautions
- Saquinavir and Saquinavir mesylate are not equivalent
- Adverse Effects
- Nephrolithiasis (Indinavir)
- Severe Diarrhea (Nelfinavir)
- Hepatotoxicity
- Associated with concurrent use of other HIV agents
- Associated with comorbid Hepatitis C
- Lipodystrophy
- Osteopenia
- Insulin Resistance
- Manage with lifestyle changes (diet, Exercise)
- Consider medications
- Thiazolidinediones (eg Rosiglitazone, Pioglitazone)
- Glucophage
- Severe lipid abnormalities
- Effects
- Hypertriglyceridemia
- Low HDL
- Management
- Can be treated with Pravastatin (see below)
- Resolves with discontinuation of Protease Inhibitor
- Drug Interactions
- Drug interactions are common
- PIs cause most interactions of all Antiretrovirals
- Statin drugs (used for PI-induced lipid abnormalities)
- Pravastatin is first choice Statin for use with PI
- Do not use Simvastatin or Lovastatin with PI
- Use Atorvastatin and Fluvastatin with caution with PI
- Monitoring
- Fasting lipid panel with glucose every 3-6 months
HIV Protease Inhibitors (C0162714)
|
|---|
| Definition (MSH) | Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. |
| Concepts | Pharmacologic Substance (T121)
|
| English | HIV PROTEASE INHIB, HIV protease inhibitor, HIV Protease Inhibitors |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree